Description

Elanco Animal Health Unlocks A Stronger Pet Health Story With Zenrelia, Credelio Quattro & Befrena!

Elanco Animal Health reported its second quarter 2026 results showing continued momentum across its diversified animal health portfolio. The company achieved reported revenue of $1.368 billion, marking a 10% increase year-over-year, with an organic constant currency revenue growth of 8%. Growth was balanced between Pet Health, which grew 11% organically, and Farm Animal, which grew 5%. Within Pet Health, the U.S. segment led with 11% growth driven by innovation products such as Zenrelia and Credelio Quattro, as well as strong performance in both veterinary clinics and retail channels. International Pet Health grew 9%, supported by these same innovations and the growth of the OTC parasiticide AdTab. For Farm Animal, the U.S. market grew 11%, led by cattle and the product Experior, while international Farm Animal grew slower at 2%, reflecting shipment timing effects.